Objective Lupus nephritis (LN) is a prevalent renal manifestation in patients with SLE, with kidney biopsy remaining the gold ...

Purpose Medication non-adherence occurs frequently in individuals with systemic lupus erythematosus (SLE); proportions as high as 43–75% have been documented, depending on the methods of assessment. 1 ...

SLE is a complex autoimmune disease with considerable unmet need. Numerous clinical trials designed to investigate novel therapies are actively enrolling patients straining limited resources and ...

Objectives To evaluate the Systemic Lupus International Collaborating Clinics-Frailty Index (SLICC-FI) as a predictor of hospitalisations in patients with SLE from a Latin American cohort. Methods ...

Objective Although SLE disproportionately affects minority racial groups, they are significantly under-represented in clinical trials in the USA. This may lead to misleading conclusions in race-based ...

Background Voclosporin (VCS) is a novel high potency calcineurin inhibitor (CNI) with a favorable metabolic profile and a consistent predictable dose response potentially eliminating the need for ...

Background Oral glucocorticoids (OCS) remain one of the most important treatments for SLE but are associated with damage. Evidence regarding the real-world use of OCS in nationwide SLE populations is ...

Objectives To identify antiphospholipid antibody-associated thrombocytopenia (aPLs-TP) phenotypes and assess their clinical outcomes. Methods This single-centre, prospective cohort study (January 2012 ...

Objective This retrospective analysis evaluated the prognostic value of renal response status 2 years after biopsy-proven lupus nephritis (LN) for the prediction of long-term renal outcomes. Methods ...

Background Immunogenicity to SARS-CoV-2 vaccination in patients with SLE varies by vaccine type and immune-modulating therapy. However, data in Southeast Asian populations, especially among Thai ...

Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the ...

Purpose Neuropsychiatric manifestations in patients with systemic lupus erythematosus (SLE) can have many underlying causes, including inflammation (inflammatory NPSLE). Inflammatory NPSLE is rare and ...